Neurizon Therapeutics Limited
Neurizon Therapeutics Limited
Your view on NUZ.AX
Overview
What the company does, where it operates, and who runs it.
About Neurizon Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ben Dingle
- Headquarters
- Suite 2, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ben Dingle
- Headquarters
- Suite 2, Melbourne, VIC, AU
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases.
Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.
Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Neurizon Therapeutics Limited. Starting points for Neurizon Therapeutics Limited: EPS -AUD 0.01, beta 1.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Neurizon Therapeutics Limited. Neurizon Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Neurizon Therapeutics Limited. Trailing twelve-month EPS for Neurizon Therapeutics Limited stands at -AUD 0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Neurizon Therapeutics Limited. Neurizon Therapeutics Limited has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ONCYOncolytics Biotech Inc. | Healthcare | NASDAQ | $35.1M | ||
| ONPHOncology Pharma Inc. | Healthcare | OTC | $109,553 | ||
| ONTTFOxford Nanopore Technologies plc | Healthcare | OTC | $1.8B | ||
| OPORFhVIVO plc | Healthcare | OTC | $59.2M | ||
| ORGSOrgenesis Inc. | Healthcare | OTC | $3.0M | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | NASDAQ | $764.9M | ||
| ORKAOruka Therapeutics, Inc. | Healthcare | NASDAQ | $6.5B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $155.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $42.0M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Neurizon Therapeutics Limited. Coverage tracks Neurizon Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Neurizon Therapeutics Limited.